KalVista Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2014 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
KalVista Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2014 to Q1 2024.
  • KalVista Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending April 30, 2024 was $3.81M, a 29.8% decline year-over-year.
  • KalVista Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending April 30, 2024 was $13.8M, a 23.2% decline year-over-year.
  • KalVista Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $13.8M, a 23.2% decline from 2022.
  • KalVista Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $18M, a 25.9% increase from 2021.
  • KalVista Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was $14.3M, a 22.2% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $13.8M $3.81M -$1.62M -29.8% Feb 1, 2024 Apr 30, 2024 10-K 2024-07-11
Q4 2023 $15.4M $4.12M -$1.52M -26.9% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-11
Q3 2023 $16.9M $2.1M -$1.53M -42.2% Aug 1, 2023 Oct 31, 2023 10-Q 2023-12-07
Q2 2023 $18.5M $3.78M +$502K +15.3% May 1, 2023 Jul 31, 2023 10-Q 2023-09-07
Q1 2023 $18M $5.42M +$2.72M +101% Feb 1, 2023 Apr 30, 2023 10-K 2024-07-11
Q4 2022 $15.2M $5.64M +$1.43M +33.8% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-11
Q3 2022 $13.8M $3.63M -$327K -8.27% Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-07
Q2 2022 $14.1M $3.27M -$133K -3.9% May 1, 2022 Jul 31, 2022 10-Q 2023-09-07
Q1 2022 $14.3M $2.7M -$388K -12.6% Feb 1, 2022 Apr 30, 2022 10-K 2024-07-11
Q4 2021 $14.7M $4.22M +$1.61M +61.6% Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-09
Q3 2021 $13.1M $3.95M +$1.6M +67.9% Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-08
Q2 2021 $11.5M $3.41M -$222K -6.12% May 1, 2021 Jul 31, 2021 10-Q 2022-09-08
Q1 2021 $11.7M $3.09M +$838K +37.3% Feb 1, 2021 Apr 30, 2021 10-K 2023-07-10
Q4 2020 $10.8M $2.61M -$824K -24% Nov 1, 2020 Jan 31, 2021 10-Q 2022-03-10
Q3 2020 $11.7M $2.36M -$1.03M -30.4% Aug 1, 2020 Oct 31, 2020 10-Q 2021-12-09
Q2 2020 $12.7M $3.63M +$1.4M +63% May 1, 2020 Jul 31, 2020 10-Q 2021-09-09
Q1 2020 $11.3M $2.25M -$608K -21.3% Feb 1, 2020 Apr 30, 2020 10-K 2022-07-07
Q4 2019 $11.9M $3.43M +$729K +27% Nov 1, 2019 Jan 31, 2020 10-Q 2021-03-11
Q3 2019 $11.2M $3.39M +$1.8M +113% Aug 1, 2019 Oct 31, 2019 10-Q 2020-12-10
Q2 2019 $9.38M $2.23M +$247K +12.5% May 1, 2019 Jul 31, 2019 10-Q 2020-09-14
Q1 2019 $9.13M $2.86M +$544K +23.5% Feb 1, 2019 Apr 30, 2019 10-K 2021-07-13
Q4 2018 $8.58M $2.7M +$3.59M Nov 1, 2018 Jan 31, 2019 10-Q 2020-03-10
Q3 2018 $4.99M $1.59M +$638K +67.1% Aug 1, 2018 Oct 31, 2018 10-Q 2019-12-03
Q2 2018 $4.35M $1.98M +$1.45M +277% May 1, 2018 Jul 31, 2018 10-Q 2019-09-09
Q1 2018 $2.9M $2.31M +$1.46M +172% Feb 1, 2018 Apr 30, 2018 10-K 2020-07-01
Q4 2017 $1.44M -$888K -$1.36M -288% Nov 1, 2017 Jan 31, 2018 10-Q 2019-03-14
Q3 2017 $2.8M $951K +$221K +30.3% Aug 1, 2017 Oct 31, 2017 10-Q 2018-12-14
Q2 2017 $2.58M $525K -$1.16M -68.8% May 1, 2017 Jul 31, 2017 10-Q 2018-09-14
Q1 2017 $3.74M $850K Feb 1, 2017 Apr 30, 2017 10-K 2019-07-16
Q4 2016 $473K -$1.39M -74.6% Nov 1, 2016 Jan 31, 2017 10-Q 2018-03-16
Q3 2016 $730K Aug 1, 2016 Oct 31, 2016 10-Q 2017-12-14
Q2 2016 $1.68M +$5.03M May 1, 2016 Jul 31, 2016 10-Q 2017-09-14
Q4 2015 $1.86M Nov 1, 2015 Jan 31, 2016 10-Q 2017-03-16
Q2 2015 -$3.35M -$3.15M -1581% Apr 1, 2015 Jun 30, 2015 10-Q 2015-08-13
Q1 2015 -$283K -$124K -78% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-21
Q2 2014 -$199K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 -$159K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.